Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 29 | ICEECE2012 | Next issue

15th International & 14th European Congress of Endocrinology


Graves' orbitopathy (GO)

ea0029s43.1 | Graves' orbitopathy (GO) | ICEECE2012

Immunopathogenesis of Graves’ orbitopathy

Bahn R.

Graves’ orbitopathy (GO) is an inflammatory autoimmune disorder of the orbit. The close clinical and temporal relationships between Graves’ hyperthyroidism and GO suggest that both conditions derive from a single systemic process and share the thyrotropin receptor (TSHR) as autoantigen. Autoimmunity directed against the TSHR on orbital fibroblasts sets in motion connective tissue remodeling within the orbit that leads to the various clinical expressions of the diseas...

ea0029s43.2 | Graves' orbitopathy (GO) | ICEECE2012

How to restore euthyroidism in the presence of Graves’ orbitopathy? Is there a best way?

Hegedus L.

Around 50% of patients with Graves’ disease (GD) have Graves’ orbitopathy (GO). However, only 5–10% have overt active disease which merits more than symptomatic treatment. Clearly, the best treatment is prophylaxis related to avoiding tobacco smoking and to obtain and maintain euthyroidism.Whether antithyroid drugs (ATDs), radioiodine (RAI), or thyroidectomy should be chosen for therapy of GD, whether or not there is presence of active GO,...

ea0029s43.3 | Graves' orbitopathy (GO) | ICEECE2012

Progress in immunosuppressive treatment of GO (selenium, steroid dosage, rituximab)

Bartalena L.

Management of Graves’ orbitopathy (GO) is a challenge, and 30–50% of patients are eventually dissatisfied with medical treatment outcome. GO natural history is poorly understood, but some patients experience a progression of GO over time. Thus, prevention of development/progression by abolishing risk factors (e.g. smoking, thyroid dysfunction) is important. The recent results of a randomized clinical trial (RCT) carried out by the EUGOGO group showed that selenium (s...